NJ A2001

Drug manufacturers and wholesale drug distributors would be exempt from pharmacist licensing requirements when distributing dialysate drugs and devices for home dialysis to patients with end-stage renal disease

Dialysate drugs and devices must be FDA-approved, held by properly registered entities, and delivered in original sealed packaging from the manufacturing facility

Delivery is permitted only upon receipt of a physician's order and must go directly to the patient, patient's designee, or a health care provider/institution administering the therapy

Manufacturers must contract with a board-registered consultant pharmacist to provide weekly quality assurance assessments of home dialysis drug storage and distribution

The law would take effect on the first day of the third month following enactment